Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Verrica Pharmaceuticals (VRCA) Change in Cash (2021 - 2025)

Historic Change in Cash for Verrica Pharmaceuticals (VRCA) over the last 5 years, with Q3 2025 value amounting to $5.7 million.

  • Verrica Pharmaceuticals' Change in Cash rose 16354.92% to $5.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.9 million, marking a year-over-year increase of 9696.49%. This contributed to the annual value of -$23.2 million for FY2024, which is 16582.19% down from last year.
  • Per Verrica Pharmaceuticals' latest filing, its Change in Cash stood at $5.7 million for Q3 2025, which was up 16354.92% from -$14.2 million recorded in Q2 2025.
  • Verrica Pharmaceuticals' 5-year Change in Cash high stood at $34.7 million for Q1 2022, and its period low was -$20.6 million during Q1 2024.
  • Moreover, its 5-year median value for Change in Cash was -$4.8 million (2023), whereas its average is $547947.4.
  • The largest annual percentage gain for Verrica Pharmaceuticals' Change in Cash in the last 5 years was 32511.38% (2023), contrasted with its biggest fall of 92005.56% (2023).
  • Verrica Pharmaceuticals' Change in Cash (Quarter) stood at -$4.7 million in 2021, then soared by 138.38% to $1.8 million in 2022, then crashed by 920.06% to -$14.8 million in 2023, then surged by 258.32% to $23.4 million in 2024, then plummeted by 75.61% to $5.7 million in 2025.
  • Its Change in Cash stands at $5.7 million for Q3 2025, versus -$14.2 million for Q2 2025 and -$16.7 million for Q1 2025.